Neovici Holding AB (publ) (IDLDX) Fair Value & Analysis
Healthcare · Market cap 91.0M SEK (≈ $9.5M) · ISIN SE0003883990
Risks
Fair value as of: Aug 22, 2026
From 1 valuation models · updated 8 days ago
Share price −4.2% over the past month.
Below-average quality, and trading another 241% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 0.1500). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (kr 0.0800 to kr 0.1500) leaves room in how you read the outcome.
Price vs Fair Value (15 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
15‑month range kr 0.2590 – kr 0.5900 · fair‑value band kr 0.0800 – kr 0.1500 · the kr 0.4090 price screens above the kr 0.1200 fair value. Dashed = 300-day average. As of Aug 22, 2026.
Analysis
Neovici Holding AB (publ) (IDLDX) currently trades at kr 0.4090, while our model-based Fair Value estimate is kr 0.1200, implying the stock looks roughly 70.7% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Neovici Holding AB (publ) generated revenue of 54.5M SEK at a net margin of -15.4%. Revenue grew 9.3% year over year. It earns a return on equity of -6.5%. The balance sheet holds a net cash position of 23.3M SEK. Fundamentals as of Aug 22, 2026
Our scenario range runs from kr 0.0800 (bear case) to kr 0.1500 (bull case); at kr 0.4090, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 64% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -71%, IDLDX screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when IDLDX reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever.
Full company description
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Neovici Holding AB (publ) reported revenue of kr 53.1M in FY2025 versus kr 12.0M in FY2021, a compound +45.1%/yr. Reported net income was −kr 12.2M in FY2025.
IDLDX screens 71% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 140 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $630.70 | $308.19 | -51% |
| Danaher Corporation DHR | $215.68 | $103.88 | -52% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 587.80 | CHF 259.80 | -56% |
| IDEXX Laboratories, Inc IDXX | $553.44 | $255.77 | -54% |
| Agilent Technologies, Inc A | $155.08 | $61.53 | -60% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | -44% |
| Illumina, Inc ILMN | $224.84 | $95.51 | -58% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | -57% |
Compare Neovici Holding AB (publ) with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Neovici Holding AB (publ) (IDLDX) overvalued or undervalued?
What is the fair value of IDLDX?
What is the quality score of IDLDX?
What is the revenue of Neovici Holding AB (publ) (IDLDX)?
What is the net profit margin of IDLDX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Neovici Holding AB (publ) in the live analysis
One click puts Neovici Holding AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.